Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Finished Goods (2020 - 2025)

Historic Finished Goods for Puma Biotechnology (PBYI) over the last 6 years, with Q3 2025 value amounting to $439000.0.

  • Puma Biotechnology's Finished Goods fell 393.87% to $439000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $439000.0, marking a year-over-year decrease of 393.87%. This contributed to the annual value of $783000.0 for FY2024, which is 3809.52% up from last year.
  • As of Q3 2025, Puma Biotechnology's Finished Goods stood at $439000.0, which was down 393.87% from $762000.0 recorded in Q2 2025.
  • Puma Biotechnology's Finished Goods' 5-year high stood at $1.6 million during Q1 2022, with a 5-year trough of $186000.0 in Q4 2022.
  • For the 5-year period, Puma Biotechnology's Finished Goods averaged around $703750.0, with its median value being $630000.0 (2022).
  • As far as peak fluctuations go, Puma Biotechnology's Finished Goods plummeted by 8389.61% in 2022, and later surged by 20483.87% in 2023.
  • Over the past 5 years, Puma Biotechnology's Finished Goods (Quarter) stood at $1.2 million in 2021, then tumbled by 83.9% to $186000.0 in 2022, then soared by 204.84% to $567000.0 in 2023, then skyrocketed by 38.1% to $783000.0 in 2024, then tumbled by 43.93% to $439000.0 in 2025.
  • Its last three reported values are $439000.0 in Q3 2025, $762000.0 for Q2 2025, and $561000.0 during Q1 2025.